CA2006929C - Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs - Google Patents

Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs Download PDF

Info

Publication number
CA2006929C
CA2006929C CA002006929A CA2006929A CA2006929C CA 2006929 C CA2006929 C CA 2006929C CA 002006929 A CA002006929 A CA 002006929A CA 2006929 A CA2006929 A CA 2006929A CA 2006929 C CA2006929 C CA 2006929C
Authority
CA
Canada
Prior art keywords
polypeptide
protein
wound
plasmid
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002006929A
Other languages
English (en)
French (fr)
Other versions
CA2006929A1 (en
Inventor
Rachel Guy
Amos Panet
Tikva Vogel
Avigdor Levanon
Moshe Werber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of CA2006929A1 publication Critical patent/CA2006929A1/en
Priority to US08/259,569 priority Critical patent/US5679320A/en
Priority to US08/409,750 priority patent/US5965383A/en
Priority to US08/826,885 priority patent/US5869616A/en
Priority to US08/909,140 priority patent/US6121426A/en
Priority to US09/492,971 priority patent/US7087722B1/en
Application granted granted Critical
Publication of CA2006929C publication Critical patent/CA2006929C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
CA002006929A 1988-12-29 1989-12-29 Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs Expired - Lifetime CA2006929C (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US08/259,569 US5679320A (en) 1988-12-29 1994-06-14 Fibrin binding domain polypeptides and uses and methods of producing same
US08/409,750 US5965383A (en) 1988-12-29 1995-03-24 Fibrin binding domain polypeptides and uses and methods of producing same
US08/826,885 US5869616A (en) 1988-12-29 1997-04-08 Fibrin binding domain polypeptides and uses and methods of producing same
US08/909,140 US6121426A (en) 1988-12-29 1997-08-11 Fibrin binding domain polypeptides and uses and methods of producing same
US09/492,971 US7087722B1 (en) 1988-12-29 2000-01-27 Fibrin binding domain polypeptides and uses and methods of producing same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29195188A 1988-12-29 1988-12-29
US291,915 1988-12-29
US34595289A 1989-04-28 1989-04-28
US345,952 1989-04-28

Publications (2)

Publication Number Publication Date
CA2006929A1 CA2006929A1 (en) 1990-06-29
CA2006929C true CA2006929C (en) 2005-10-18

Family

ID=26967068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002006929A Expired - Lifetime CA2006929C (en) 1988-12-29 1989-12-29 Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs

Country Status (8)

Country Link
EP (1) EP0451211A4 (da)
JP (1) JP3095771B2 (da)
KR (1) KR910700339A (da)
AU (1) AU636596B2 (da)
CA (1) CA2006929C (da)
DK (2) DK128091A (da)
IL (1) IL92925A0 (da)
WO (1) WO1990007577A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11290885B2 (en) 2018-12-19 2022-03-29 Rohde & Schwarz Gmbh & Co. Kg Communication system and method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5792742A (en) * 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
GB9401689D0 (en) * 1994-01-28 1994-03-23 Univ Manchester Diagnosis and treatment of endocarditis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) * 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11290885B2 (en) 2018-12-19 2022-03-29 Rohde & Schwarz Gmbh & Co. Kg Communication system and method

Also Published As

Publication number Publication date
IL92925A0 (en) 1990-09-17
KR910700339A (ko) 1991-03-14
DK5693A (da) 1993-01-18
JP3095771B2 (ja) 2000-10-10
JPH04505698A (ja) 1992-10-08
DK128091D0 (da) 1991-06-28
CA2006929A1 (en) 1990-06-29
AU636596B2 (en) 1993-05-06
WO1990007577A1 (en) 1990-07-12
EP0451211A4 (en) 1992-09-09
AU4959890A (en) 1990-08-01
EP0451211A1 (en) 1991-10-16
DK5693D0 (da) 1993-01-18
DK128091A (da) 1991-08-29

Similar Documents

Publication Publication Date Title
US6121426A (en) Fibrin binding domain polypeptides and uses and methods of producing same
EP0407008A2 (en) Fibronectin fragment
US5238919A (en) Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
WO1994015953A1 (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
WO1994015953A9 (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
WO1992019279A1 (en) Phospholipid-targeted thrombolytic agents
WO1990010694A1 (fr) Nouvelle superoxyde dismutase
NZ237244A (en) Cloning and production of human von willebrand factor analogues and compositions thereof
CA2006929C (en) Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs
AU730333B2 (en) Inhibitors of the urokinase receptor
US5679320A (en) Fibrin binding domain polypeptides and uses and methods of producing same
JP2002510709A (ja) 二重Ａｖｂ３及び転移関連受容体リガンド
EP0329413A2 (en) Polypeptides with cell-spreading activity
CA1335577C (en) Superoxide dismutase analogs having novel binding properties
US7087722B1 (en) Fibrin binding domain polypeptides and uses and methods of producing same
JPH04210700A (ja) 組換ヒトトロンボモジュリン誘導体
US5316934A (en) Effective thrombosis mediated by human prourokinase-like polypeptides with increased binding affinity for thrombosis
JP2002522504A (ja) 多価ａｖｂ３および転移関連レセプター・リガンド
WO1995028955A1 (en) PEPTIDES BINDING TO THE α2-MACROGLOBULIN RECEPTOR/LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN
HK1013255B (en) Fibrin binding domain polypeptides and uses and methods of producing same
JPH0454199A (ja) 機能性ポリペプチド
MXPA99009109A (en) Inhibitors for urokinase receptor
EP0424512A1 (en) ANTIMETASTATIC PEPTIDES.
JPH07224100A (ja) 新規トロンボモジュリン類

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry